Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Boehringer Ingelheim
Citi
Medtronic
Chinese Patent Office
Chubb
Julphar
AstraZeneca
Teva
US Army

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,466,137

« Back to Dashboard

Summary for Patent: 8,466,137
Title:Testosterone gel and method of use
Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gen formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.
Inventor(s): Malladi; Ramana (Marietta, GA), Stahlman; Jodi (Smyrna, GA)
Assignee: Unimed Pharmaceuticals, LLC (Marietta, GA) Laboratoires Besins International, SAS (Paris, FR)
Application Number:13/180,327
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,466,137

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Abbvie ANDROGEL testosterone GEL, METERED;TRANSDERMAL 022309-001 Apr 29, 2011 AB RX Yes Yes ➤ Subscribe ➤ Subscribe TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE ➤ Subscribe
Abbvie ANDROGEL testosterone GEL;TRANSDERMAL 022309-002 Sep 7, 2012 AB2 RX Yes No ➤ Subscribe ➤ Subscribe TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE ➤ Subscribe
Abbvie ANDROGEL testosterone GEL;TRANSDERMAL 022309-003 Sep 7, 2012 AB2 RX Yes Yes ➤ Subscribe ➤ Subscribe TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,466,137

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,741,881 Testosterone gel and method of use ➤ Subscribe
8,466,136 Testosterone gel and method of use ➤ Subscribe
8,466,138 Testosterone gel and method of use ➤ Subscribe
8,754,070 Testosterone gel and method of use ➤ Subscribe
8,729,057 Testosterone gel and method of use ➤ Subscribe
8,486,925 Testosterone gel and method of use ➤ Subscribe
8,759,329 Testosterone gel and method of use ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,466,137

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ukraine 87627 ➤ Subscribe
Slovenia 1937276 ➤ Subscribe
Tunisia SN08167 ➤ Subscribe
Serbia 52671 ➤ Subscribe
Portugal 1937276 ➤ Subscribe
New Zealand 567056 ➤ Subscribe
Norway 20082170 ➤ Subscribe
Morocco 29941 ➤ Subscribe
Japan 5728508 ➤ Subscribe
South Korea 20080068654 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Chinese Patent Office
Fish and Richardson
Queensland Health
Citi
Julphar
US Army
McKesson
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot